MAPKAPK2 and glioblastoma: When glioblastoma cell lines with different p53 and EGFR backgrounds were treated with CMPD1, the expected decrease in cell proliferation for all cell types was observed at concentrations in line with the reported Ki of MK2 phosphorylation (Figure 1a).